1488 / 1674
Who decides?
Low risk:
the same in NL, UK, B, It, D, …?
•
Countries with 5 y endocrine therapy for ALL ER+
•
Countries with endocrine therapy starting at intermediate
risk
(≥ 5% recurrence or survival benefit)
•
Side effects:
•
Very (too?) well documented and known for RT
•
Emerging knowledge for systemic therapy…
RT after tumorectomy: not always required?
Less local treatment: where is the limit?